Monica Prasad-Hayes

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Kathleen N. Moore, Amit M. Oza, Nicoletta Colombo et al. · Annals of Oncology · 2021 · 265 citations · Full text

Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers

Elena Pereira, Olga Camacho‐Vanegas, Sanya Anand et al. · PLoS ONE · 2015 · 174 citations · Full text

Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer

Melissa K. Frey, Annie E. Ellis, Kristen Zeligs et al. · American Journal of Obstetrics and Gynecology · 2020 · 120 citations · Full text

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Ignace Vergote, Giovanni Scambia, David M. O’Malley et al. · The Lancet Oncology · 2019 · 85 citations · Full text

Advanced Ovarian Cancer, Medicine, Pharmacology +9

Ovarian Cancer Treatment and Survival Trends Among Women Older Than 65 Years of Age in the United States, 1995–2008

Jenny J. Lin, Natalia Egorova, Rebeca Franco et al. · Obstetrics and Gynecology · 2015 · 51 citations · Full text